Results 141 to 150 of about 4,567,849 (254)

Therapeutic potential of a Bax inhibitor‐1/TMBIM6 antagonist (BIA) and its analogues in Aspergillus fumigatus‐induced asthma via dual targeting of AKT and epithelial‐derived inflammatory cytokines

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 19, Page 5975-5991, October 2026.
Background and Purpose Aspergillus fumigatus (A. fumigatus) exposure causes of severe allergic asthma, characterized by airway inflammation and epithelial dysfunction. TMBIM6 (Bax inhibitor‐1) has been implicated in airway epithelial stress responses and AKT signalling.
Young‐Jin Yu   +7 more
wiley   +1 more source

Acute irradiation causes a long-term disturbance in the heterogeneity and gene expression profile of medullary thymic epithelial cells. [PDF]

open access: yesFront Immunol, 2023
Horie K   +12 more
europepmc   +1 more source

Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies

open access: yesEuropean Journal of Clinical Investigation, Volume 56, Issue 10, October 2026.
COPD is a heterogeneous disease driven by overlapping neutrophilic and eosinophilic inflammatory pathways. This review highlights the shift from symptom‐based treatment toward phenotype‐ and biomarker‐directed care. Blood eosinophils, FeNO, and IgE predict corticosteroid responsiveness and identify candidates for biologic therapy.
Sasha Raman   +3 more
wiley   +1 more source

d‐Sorbose Promotes Regulatory T‐Cell Differentiation and Ameliorates Autoimmune and Allergic Diseases via Hexosamine Biosynthetic Pathway Inhibition

open access: yesThe FASEB Journal, Volume 40, Issue 17, 15 September 2026.
d‐Sorbose promotes Foxp3+ Treg differentiation ex vivo and exerts potent anti‐inflammatory effects in vivo, ameliorating allergic airway inflammation and preventing autoimmune diabetes without compromising T cell viability or inducing toxicity.
Fumiaki Sato   +12 more
wiley   +1 more source

Extrusion Bioprinting for Wound Healing: Innovations in Functionalized Bioinks and Bioprinting Technology

open access: yesAdvanced Materials Technologies, Volume 11, Issue 18, 18 September 2026.
Extrusion‐based bioprinting (EBB) has emerged as a versatile biofabrication platform capable of precisely depositing bioinks composed of biomaterials, cells, and bioactive agents to generate patient‐specific, biomimetic skin constructs. This paper presents a state‐of‐the‐art and forward‐looking overview of EBB for wound healing, encompassing printing ...
Hien‐Phuong Le   +4 more
wiley   +1 more source

Somatic Mutations of Thymic Epithelial Tumors Identified in the Prospective THYMOGENE Trial

open access: yesThoracic Cancer
Background The molecular landscape of thymic epithelial tumors has been partially elucidated. GTF2I mutation drives the pathogenesis in approximately 50% of tumors; however, the key molecular aberrations in the other cases remain unclear.
Eleonora Pardini   +16 more
doaj   +1 more source

Editorial: Thymus function and aging: A focus on thymic epithelial cells. [PDF]

open access: yesFront Immunol, 2022
Shichkin VP   +3 more
europepmc   +1 more source

IL‐7R‐Enriched Extracellular Vesicles From the Thymus Drive Colitis via Promoting Neutrophil Extracellular Trap Formation

open access: yesAdvanced Science, Volume 13, Issue 49, 3 September 2026.
Inflammatory bowel disease (IBD) pathogenesis remains unclear. This study reveals that thymus‐originated IL‐7R‐enriched extracellular vesicles exacerbate colitis by promoting neutrophil extracellular traps via a thymus‐gut axis, uncovering an inter‐organ communication mechanism in inflammatory bowel disease pathogenesis.
Yao Liao   +21 more
wiley   +1 more source

Transcriptomic diversity in human medullary thymic epithelial cells. [PDF]

open access: yesNat Commun, 2022
Carter JA   +8 more
europepmc   +1 more source

Extent of Sinus Surgery Is Associated With Disease Control in Biologic Treated Type 2 Dominant CRS

open access: yesInternational Forum of Allergy &Rhinology, Volume 16, Issue 9, Page 986-995, September 2026.
ABSTRACT Background A greater benefit of biologics is observed after surgery in Type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). However, the extent of surgery remains undefined in many studies. This study evaluated the extent of surgery on disease control in patients receiving biologics for refractory Type 2 dominant CRSwNP.
Nicholas J. Campion   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy